Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2011-08-16
2011-08-16
Belyavskyi, Michail A (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S577000, C514S885000
Reexamination Certificate
active
07998481
ABSTRACT:
The present invention relates to methods and compositions for treating and/or preventing autoimmune and/or inflammatory disease. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells, NK cells and/or NKT cells, by modulating NKG2D.
REFERENCES:
patent: 6262244 (2001-07-01), Houchins et al.
patent: 6458350 (2002-10-01), Cosman et al.
patent: 6541610 (2003-04-01), Smith
patent: 6653447 (2003-11-01), Cosman et al.
patent: 2002/0187151 (2002-12-01), Raulet et al.
patent: 2003/0095965 (2003-05-01), Van Beneden et al.
patent: 2003/0165835 (2003-09-01), Spies et al.
patent: 2003/0171280 (2003-09-01), Soderstrom
patent: 2004/0115198 (2004-06-01), Spies et al.
patent: 2005/0158307 (2005-07-01), Spies et al.
patent: 2005/0233391 (2005-10-01), Spies et al.
patent: 2007/0077241 (2007-04-01), Spies et al.
patent: 2008/0260727 (2008-10-01), Lanier et al.
patent: WO-99/52877 (1999-10-01), None
patent: WO 01/71005 (2001-09-01), None
patent: WO 02/068615 (2002-09-01), None
patent: WO 03/029436 (2003-04-01), None
patent: WO 03/089616 (2003-10-01), None
patent: WO-2004/087739 (2004-10-01), None
Atkinson et al., Nature, 1999, V.5, pp. 601-604.
Mestas et al., J. of Immunology, 2004, 172, pp. 2731-3238.
Teuveson et al., Immun. Review 1993, N136, pp. 101-107.
Goronzy and Weyand, “T-cell regulation in rheumatoid arthritis,”Curr Opin Rheumatol, 16:212-217, 2004.
Groh et al., “Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium,”Proc Natl Acad Sci, USA, 93:12445-12450, 1996.
Groh et al., “Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells,”Science, 279:1737-1740, 1998.
Groh et al., “Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB,”Proc Natl Acad Sci, USA, 96:6879-6884, 1999.
Groh et al., “Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation,”Nature, 419:734-738, 2002.
Lanier, “Turning on natural killer cells,”J Exp Med, 191:1259-1262, 2000.
Lanier, “On guard—activating NK cell receptors,”Nat Immunol, 2:23-27, 2001.
Li et al., “Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA,”Nat Immunol, 2:443-451, 2001.
Moser et al., “CD94-NKG2A receptors regulate antiviral CD8+ T cell responses,”Nat Immunol, 3:189-195, 2002.
Schrambach et al., “In vivo expression pattern of MICA and MICB and its relevance to auto-immunity and cancer,”PLoS One, 2:e528, 2007.
Ravetech and Lanier, “Immune inhibitory receptors,”Science, 290:84-89, 2000.
Warrington et al., “CD4+, CD28− T cells in rheumatoid arthritis patients combine features of the innate and adaptive immune systems,”Arthritis Rheum, 44:13-20, 2001.
Yen et al., “Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis,”J Exp Med, 193:1159-1167, 2001.
Bakker et al., DAP12-deficient mice fail to develop autoimmunity due to impaired antigen priming,Immunity, 13: 345-353, 2000.
Baron et al., Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection,Immunity, 16: 583-594, 2002.
Carayannopoulos et al., “Ligands for murine NKG2D display heterogeneous binding behavior,”Eur J Immunol, 32: 597-605, 2002.
Carayannopoulos et al., “Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D,”J Immunol, 169: 4079-83, 2002.
Cerwenka et al., “Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice,”Immunity, 12: 721-727, 2000.
Chisari and Ferrari, “Hepatitis B virus immunopathogenesis,”Annu Rev Immunol, 13: 29-60, 1995.
Chisari et al., “Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice,”Proc Natl Acad Sci USA, 84: 6909-6913, 1987.
Cosman et al., “ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor,”Immunity, 14: 123-33, 2001.
Diefenbach et al., “Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D,”Nat Immunol, 3: 1142-1149, 2002.
Ferrari et al., “Immunopathogenesis of hepatitis B,”B J Hepatol, 39: S36-S43, 2003.
George et al., “Tolerance and alloreactivity of the Ly49D subset of murine NK cells,”J Immunol, 163: 1859-1867, 1999.
Groh et al., “Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis,”Proc Natl Acad Sci USA, 100: 9452-9457, 2003.
Guidotti et al., “High-level hepatitis B virus replication in transgenic mice,”J Virol, 69: 6158-6169, 1995.
Hue et al., “A direct role for NKG2D/MICA interaction in villous atrophy during celeic disease,”Immunity, 21: 367-377, 2004.
Jamieson et al., “The role of the NKG2D immunoreceptor in immune cell activation and natural killing,”Immunity, 17: 19-29, 2002.
Kiessling et al., “Evidence for a similar or common mechanism for natural killer cell activity and resistance to hemopoietic grafts,”Eur J Immunol, 7: 655-663, 1977.
Lauer and Walker, “Hepatitis C virus infection,”N Engl J Med, 345: 41-52, 2001.
Lodoen et al., “NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp140 modulation of retinoic acid early inducible 1 gene molecules,”J Exp Med, 197: 1245-1253, 2003.
Lodoen et al., “The cytomegalovirus m155 gene product subverts natural killer cell antiviral protection by disruption of H60-NKG2D interactions,”J Exp Med, 200: 1075-108, 2004.
Lotzova et al., “Prevention of rejection of allogeneic bone marrow transplants by NK 1.1 antiserum,”Transplantation, 35: 490-494, 1983, abstract only.
Maier et al., “Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28−/− mice,”Nat Med, 7: 557-562, 2001.
Malarkannan et al., “The molecular and functional characterization of a dominant minor H antigen, H60,”J Immunol, 161: 3501-3509, 1998.
McNerney et al., “Role of natural killer cell subsets in cardiac allograft rejection,”Am J Transplant, 6: 505-513, 2006.
Meresse et al., “Coordinated induction by IL15 of TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiec disease,”Immunity, 21: 357-366, 2004.
Murphy et al., “Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID). Evidence that natural killer cells can mediate the specificity of marrow graft rejection,”J Exp Med, 165: 1212-1217, 1987.
Murphy et al., “Acute rejection of murine bone marrow allografts by natural killer cells and T cells. Differences in kinetics and target antigens recognized,”J Exp Med, 166: 1499-1509, 1987.
Murphy et al., “Natural killer cells activated with interleukin 2 in vitro can be adoptively transferred and mediate hematopoietic histocompatibility-1 antigen-specific bone marrow rejection in vivo,”Eur J Immunol, 20: 1729-1734, 1990.
Nowbakht et al., “Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias,”Blood, 105: 3615-3622, 2005.
Ogasawara et al., “Inducible costimulator costimulates cytotoxic activity and IFN-gamma production in activated murine NK cells,”J Immunol, 169: 3676-3685, 2002.
Ogasawara et al., “Impairment of NK cell function by NKG2D modulation in NOD mice,
Kang Sang-Mo
Lanier Lewis L.
Belyavskyi Michail A
Morrison & Forester LLP
The Regents of the University of California
LandOfFree
Modulation of NKG2D for treating or preventing solid organ... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of NKG2D for treating or preventing solid organ..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of NKG2D for treating or preventing solid organ... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2772160